artemether has been researched along with cgp-56697 in 142 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (2.82) | 18.2507 |
2000's | 4 (2.82) | 29.6817 |
2010's | 13 (9.15) | 24.3611 |
2020's | 121 (85.21) | 2.80 |
Authors | Studies |
---|---|
Bojang, K; Doherty, T; Gathmann, I; Gemperli, B; Greenwood, B; Haywood, M; Jaffar, S; Jones, P; McAdam, K; Obaro, S; Pinder, M; Royce, C; Snounou, G; von Seidlein, L | 1 |
Abdulla, S; Beck, HP; Gathmann, I; Hatz, C; Kibatala, P; Mull, R; Royce, C; Schellenberg, D; Tanner, M | 1 |
Ezzet, F; Karbwang, J; Mull, R | 1 |
Farkad, E; Karbwang, J; Mull, R; Na-Bangchang, K; Tasanor, U; Thanavibul, A | 1 |
Bindschedler, M; Ezzet, F; Lefèvre, G; Meyer, I; Schaeffer, N; Thomsen, MS | 1 |
Adaramoye, OA; Ademowo, OG; Akinsanya, AM; Fafunso, MA; Nneji, CM; Osaimoje, DO | 1 |
Kuhn, T; Wang, Y | 1 |
Arinaitwe, E; Bigira, V; Dorsey, G; Gasasira, A; Homsy, J; Kakuru, A; Kamya, MR; Katrak, S; Sandison, TG; Tappero, JW; Wanzira, H | 1 |
Oguonu, T; Okafor, HU; Shu, EN | 1 |
Ali, S; Lindegardh, N; Najmi, MH; Tarning, J | 1 |
Bashraheil, M; Bassat, Q; González, R; Kipkeu, C; Lefèvre, G; Lyimo, J; Machevo, S; Maiga, H; Mårtensson, A; Menéndez, C; Nahum, A; Nwaiwu, O; Ogutu, B; Ouma, P; Ubben, D; Walter, V | 1 |
Abiodun, OO; Akinbo, J; Ojurongbe, O | 1 |
Azandossessi, C; Damien, G; de Tove, YS; Kinde Gazard, D; Lawani, S; Ogouyèmi-Hounto, A; Remoue, F | 1 |
Cohen, J; Kasozi, H; Saran, I; Yavuz, E | 1 |
Álvarez-Larrotta, C; Aponte, S; Bernal, SD; González, C; Guerra, ÁP; Knudson-Ospina, A; Restrepo, C; Yasnot, MF | 1 |
Beavogui, AH; Borghini-Fuhrer, I; Djimdé, AA; Duparc, S; Felices, M; Funck-Brentano, C; Khan, Y; Ouedraogo, JB; Ouologuem, N; Sagara, I; Sirima, SB; Soulama, I; Voiriot, P | 1 |
Banda, CG; Barnes, KI; Maartens, G | 1 |
Amara, A; Khoo, S; Lamorde, M; Waitt, C; Walimbwa, S | 1 |
Bierhoff, M; Grobusch, MP; van Gool, T; van Hattem, JM; van Vugt, M; Visser, BJ | 1 |
Obiebi, IP | 1 |
Fungula, B; Inocencio da Luz, R; Kalabuanga, M; Lula Ntamba, Y; Lutumba, P; Muhindo Mavoko, H; Ntamabyaliro Nsengi, PM; Tona Lutete, G; Van Geertruyden, JP | 1 |
Badjanga, BB; Day, NPJ; Fanello, C; Hoglund, RM; Jackson, NV; Kabedi, C; Kayembe, D; Lee, SJ; McGready, R; Nosten, F; Onyamboko, MA; Tarning, J; Turner, GDH; White, NJ | 1 |
Abdullahi, ST; Bakare-Odunola, MT; Bolarinwa, RA; Khoo, S; Olagunju, A; Olarewaju, OJ; Owen, A; Soyinka, JO; Tarning, J; Winterberg, M | 1 |
Aweeka, F; Huang, L; Hughes, E; Kajubi, R; Mwebaza, N; Mwima, MW; Nguyen, V; Nyunt, MM; Orukan, F; Parikh, S | 1 |
Beshir, KB; Lubis, CP; Lubis, IND; Lubis, M; Sutherland, CJ; Wijaya, H | 1 |
Amir, A; De Silva, JR; Ghozali, AH; Lai, MY; Lau, YL; Liew, JWK; Mat Salleh, NH; Ng, DC; Rahman, MFA; Samsusah, S; Tan, JH | 1 |
Arroyo-Arroyo, MI; Barnes, KI; Bastiaens, GJH; Bjorkman, A; Bousema, T; Brown, JM; Chen, I; Craig, E; D'Alessandro, U; Dicko, A; Drakeley, CJ; El-Sayed, BB; Elzaki, SG; Eziefula, AC; Gonçalves, BP; Gosling, R; Guerin, PJ; Humphreys, GS; Kariuki, S; Kwambai, TK; Maestre, AE; Martensson, A; Mosha, D; Mwaiswelo, RO; Ngasala, BE; Okebe, J; Price, RN; Raman, J; Roh, ME; Samuels, AM; Sawa, P; Smit, MR; Stepniewska, K; Stone, WJR; Tiono, AB | 1 |
Clark, RL | 1 |
Iribhogbe, OI; Odoya, EM | 1 |
Al Khaja, KAJ; Sequeira, RP | 1 |
Cargill, Z; Chu, C; Gilder, ME; McGready, R; Min, AM; Nosten, F; Phyo, AP; Poe, H; Saito, M; San, TD; White, NJ; Yotyingaphiram, W | 1 |
Denti, P; Kawuma, AN; Khoo, S; Lamorde, M; Pillai, GC; Walimbwa, SI; Wasmann, RE | 1 |
Baguiya, A; Barry, N; Dianda, F; Héma, A; Hien, D; Kaboré, JMT; Kiba Koumaré, A; Kouanda, S; Nombré, Y; Savadogo, Y; Siribie, M; Sirima, SB; Soulama, I; Tchouatieu, AM; Tiono, AB | 1 |
Deng, C; Liang, Y; Lu, C; Song, J; Tan, B; Wang, Q; Wu, W; Xu, Q; Zhang, H; Zhou, C | 1 |
André, K; Bondo, BJ; Cândido, ALM; Caquece, F; Dimbu, PR; Ferreira, CM; Fortes, F; Garcia, LEA; Horth, R; Jandondo, D; Kelley, J; Labuda, S; Lucchi, N; Martins, JF; Morais, JFM; Nieto Andrade, B; Patel, D; Pembele, G; Pluciński, MM; Ponce de León, G; Svigel, SS; Talundzic, E | 1 |
Rasmussen, C; Ringwald, P | 1 |
Abba, T; Angora, EK; Assi, SB; Bedia, VA; Daho, AK; Emmanuel, B; Kiki-Barro, PMC; Konate, AA; Menan, H; Tiacoh, LN; Toure, OA; Yavo, W | 1 |
Beshir, KB; Chijioke-Nwauche, I; Nwauche, CA; Oguike, MC; Sutherland, CJ | 1 |
Bamadio, A; Barry, N; Beshir, KB; Compaore, YD; Coulibaly, M; Coulibaly, SA; Dama, S; Dao, F; Dara, N; Diallo, N; Diarra, A; Djimde, A; Fofana, B; Kaboré, JM; Kabore, NT; Kodio, A; Maurice, OS; Nikiema, F; Ouédraogo, JB; Sagara, I; Sirima, SB; Sombie, S; Somé, FA; Soulama, I; Sutherland, CJ; Togo, AH; Traore, A; Traore, OB; Zongo, I | 1 |
Ali, R; Attah, S; Ekoh, OC; Okafor, S; Okoro, U; Ugwu, D; Ugwuja, D | 1 |
Bancone, G; Carrara, VI; Chu, C; Duanguppama, J; Gilder, ME; Haohankhunnatham, W; Imwong, M; Konghahong, K; Lee, SJ; McGready, R; Min, AM; Nosten, F; Paw, MK; Phyo, AP; Pimanpanarak, M; Proux, S; Saito, M; Singhasivanon, P; Tun, NW; Turner, C; Viladpai-Nguen, J; White, NJ | 1 |
Baltzell, K; Benjamin-Chung, J; Bhangu, K; Dlamini, B; Dlamini, N; Dufour, MK; Gosling, R; Greenhouse, B; Helb, D; Hsiang, MS; Kalungero, M; Kunene, S; Malambe, C; Maphalala, G; Mngadi, N; Nhlabathi, N; Ntshalintshali, N; Pindolia, D; Prach, LM; Tesfa, G; Vilakati, S; Whittemore, B | 1 |
Gandhi, P; Renner, KC; Schmitt, EK; Straimer, J | 1 |
Callery, JJ; Ean, M; Imwong, M; Maude, RJ; Mukaka, M; Peto, TJ; Sokha, M; Sovannaroth, S; Soviet, O; Tarning, J; Tripura, R; von Seidlein, L; Vongpromek, R; Waithira, N | 1 |
Baptista-Fernandes, T; Benavente, ED; Caldas, JP; Campino, S; Cardoso, M; Clark, TG; Conceição, C; Domingos, J; Mansinho, K; Nogueira, F; Reis, A; Silva-Pinto, A; Toscano, C | 1 |
Davis, TME; Davis, WA; Hii, KC; Page-Sharp, M; Salman, S; Singh, B; Sugiarto, SR | 1 |
Achan, J; Biculu, J; Bukoma, P; Ediamu, T; Gudoi, S; Mulebeke, R; Musiime, A; Nantanda, R; Tibenderana, JK; Tumwine, D; Wanzira, H | 1 |
Asante, KP; Asiimwe, S; Barsainya, S; Boulton, C; Csermak Renner, K; Demin, I; Doumbia, S; Fofana, B; Gandhi, P; Grobusch, MP; Karita, E; Mugerwa, H; Ndayisaba, G; Oduro, A; Sayyed, S; Schmitt, EK; Straimer, J; Su, G; Venishetty, VK; Yeka, A | 1 |
Ako, BA; Assi, SB; Coulibaly, B; Gbessi, EA; Gnondjui, A; Jambou, R; Koui, TS; Sanogo, I; Sokouri, DP; Tiacoh, NL; Toure, OA | 1 |
Chapotera, G; Chirwa, T; D'Alessandro, U; Kazembe, L; Laufer, MK; Mathanga, D; Mukaka, M; Mwapasa, V; Patson, N | 1 |
Assefa, DG; Makonnen, E; Yismaw, G | 1 |
Abla, N; Barber, BE; Barnes, KI; Boyle, MJ; Chalon, S; Chughlay, MF; El Gaaloul, M; Engwerda, CR; Griffin, P; Kress, A; Marquart, L; McCarthy, JS; Möhrle, JJ; Reuter, SE; Schultz, HB; Tapley, P; van Giersbergen, P; Webster, RA; Wells, T | 1 |
Gustafsson, L; James, S; Thozhuthumparambil, KP; Zhang, Y | 1 |
Abuaku, B; Afriyie, PO; Bart-Plange, C; Duah-Quashie, NO; Ghansah, A; Gyasi, A; Koram, KA; Malm, KL; Owusu-Antwi, F; Quashie, N | 1 |
Fike, A; Hocaoğlu, M; Katz, JD; Rajasimhan, S; Schiffenbauer, A | 1 |
Aboh, PM; Adzemye, LM; Akam, LF; Ali, IM; Alifrangis, M; Ambani, MCE; Ango, Z; Bigoga, JD; Chedjou, JPK; Dinza, G; Dongmo, CH; Douanla, A; Ewane, MS; Fomboh, CT; Fosah, DA; Kotcholi, GB; Ludovic, AJ; Mbacham, WF; Moyeh, MN; Nana, WD; Ndikum, VN; Ngu, JA; Niba, PTN; Nji, AM; Nna, DRA; Oben, OLA; Omgba, PAM; Selly-Ngaloumo, AA; Tatah, FM; Ticha, JT | 1 |
Apat, D; Carter, J; Igunza, P; Kimori, J; Kinyari, T; Kiplimo, R; Langat, B; Marita, E; Muhula, S | 1 |
Baraka, V; Kamugisha, E; Kapesa, A; Kidenya, B; Konje, E; Marwa, K; Mukonzo, J; Swedberg, G | 1 |
Amaratunga, C; Callery, JJ; Chau, NH; Chotivanich, K; Chotsiri, P; Day, NPJ; Dhorda, M; Dondorp, AM; Duanguppama, J; Dung, NTP; Hien, TT; Hoglund, RM; Imwong, M; Lek, D; Long, LT; Maude, RJ; Miotto, O; Mukaka, M; Nghia, HDT; Nguon, C; Peto, TJ; Rekol, H; Ruecker, A; Sokha, M; Sovann, Y; Tarning, J; Thuong, NTH; Tripura, R; van der Pluijm, RW; Van Luong, V; von Seidlein, L; Waithira, N; White, NJ | 1 |
Das, S; Dhorda, M; Guérin, PJ; Imwong, M; Kebféné, M; Kérah-Hinzoumbé, C; Khomvarn, T; Nagorngar, TY; Saralamba, N; Sibley, CH; Srisutham, S; Vongpromek, R | 1 |
Kweka, E; Mårtensson, A; Mmbando, BP; Msolo, D; Mwaiswelo, RO; Ngasala, B | 1 |
Bauleni, A; Buchwald, AG; Chilombe, M; Coalson, JE; Cohee, LM; Laufer, MK; Mathanga, DP; Ngwira, A; Peterson, I; Schaffer-DeRoo, S; Seydel, KB; Taylor, TE; Valim, C; Wilson, ML | 1 |
Bottieau, E; Huits, R; Rosanas-Urgell, A; Tournoy, TK; Van Esbroeck, M | 1 |
Atieli, H; Debrah, I; Githeko, AK; Githure, J; Kazura, J; Lee, MC; Magomere, EO; Mukabana, WR; Ochwedo, KO; Olumeh, JO; Onyango, P; Otambo, WO; Ouma, C; Wang, C; Yan, G; Zhou, G | 1 |
Asinya, M; Jeuronlon, MK; Kamara, P; Koko, VS; Kollie, A; Ma, L; Menard, D; Nyansaiye, P; Parwon, S; Pratt, OJ; Ringwald, P; Taweh, F; Tehmeh, L; Vonhm, B; Warsame, M | 1 |
Basco, LK; Briolant, S; Casimiro, PN; Kobawila, SC; Matondo Diassivi, B; Ndounga, M; Pembet Singana, B; Ringwald, P; Youndouka, JM | 1 |
Ashaba, FK; Edgar, K; Kamya, MR; Mwesigwa, S; Nsobya, SL; Ocan, M | 1 |
Grundmann, O; Hernandez Maldonado, J | 1 |
Balizou, O; Biago, U; Gody, JC; Moyen, M; Nambei, WS; Ndoua, C; Pounguinza, S | 1 |
Batty, KT; Bwire, GM; Davis, TME; Makani, J; Manning, L; Minzi, OMS; Moore, BR; Ngasala, B; Page-Sharp, M; Salman, S; Sugiarto, SR | 1 |
Baguiya, A; Barry, N; Burri, C; Dianda, F; Hien, D; Kaboré, JMT; Nombré, Y; Siribié, M; Sirima, SB; Soulama, I; Tchouatieu, AM; Tiono, AB | 1 |
Hezagira, N; Riewpaiboon, A; Youngkong, S | 1 |
Adeniji, OE; Amambua-Ngwa, A; Amawu, AU; Correa, S; Faal, F; Heinz, E; Hughes, G; Meremikwu, MM; Oboh, MA; Ogban, E | 1 |
Obonyo, CO; Ogutu, BR | 1 |
Amante, FH; Barber, BE; Birrell, GW; Edstein, MD; Gower, J; Heunis, J; Jennings, H; Llewellyn, S; Lynch, S; Marquart, L; McCarthy, JS; Mitchell, H; O'Neill, B; Peters, JM; Potter, AJ; Shanks, GD; Webster, R | 1 |
Baguiya, A; Barry, N; Hien, D; Kaboré, JMT; Siribié, M; Sirima, SB; Soulama, I; Tchouatieu, AM; Tiono, AB | 1 |
Abuom, D; Akala, HM; Andagalu, B; Chemwor, G; Cheruiyot, A; Cowden, J; Juma, D; Kamau, E; Ogutu, B; Okoth, R; Okudo, C; Onyango, I; Opot, B; Sifuna, P; Wafubwa, J; Watson, OJ; Yalwala, S; Yeda, R | 1 |
Amambua-Ngwa, A; Bojang, F; D'Alessandro, U; Demba, MA; Diop, MF; Jeffries, D; Mane, K; Mbye, H; Mohammed, NI; Quashie, NB | 1 |
Aguas, R; Boni, MF; Gao, B; Nguyen, TD; Okell, L; Penny, MA; Smith, DL; Tran, TN; Watson, OJ | 1 |
Abdallah, KS; Bacar, A; Deng, C; Li, G; Li, M; Liu, R; Lu, C; Silai, R; Song, J; Tan, R; Wu, W; Xu, Q; Yuan, Y; Zhang, H; Zheng, S | 1 |
Amambua-Ngwa, A; Dugassa, S; Golassa, L; Jaiteh, FK; Oboh, M; Oriero, E; Tadele, G | 1 |
Buff, AM; Chebore, W; Desai, M; Kariuki, S; Otieno, K; Owidhi, M; Samuels, AM; Westercamp, N | 1 |
Barnes, KI; Berghmans, PJ; Chalon, S; Chughlay, MF; El Gaaloul, M; Escoffier, E; Flynn, J; Gobeau, N; Izquierdo-Juncàs, D; Jansen, B; Kümmel, A; Marx, MW; Mitov, V; Möhrle, JJ; Rosanas-Urgell, A; Van Geertruyden, JP; Van Leuven, K | 1 |
Chen, L; Cui, L; Guo, S; Huang, T; Huang, Y; Lu, F; Qian, J; Wang, B; Zhang, F | 1 |
Kamugisha, E; Konje, ET; Liwa, AC; Marwa, KJ; Mwita, S; Swedberg, G | 1 |
Aweeka, FT; Colt, M; Goodwin, J; Huang, L; Kajubi, R; Li, F; Mwebaza, N; Orukan, F; Parikh, S; Richards, K; Wang, K; Whalen, ME | 1 |
Callery, JJ; Chotthanawathit, P; Conradis-Jansen, F; Dondorp, AM; Duanguppama, J; Ean, M; Heng, C; Imwong, M; Jongdeepaisal, M; Khonputsa, P; Madmanee, W; Maude, RJ; Mukaka, M; Peerawaranun, P; Pell, C; Peto, TJ; Pongsoipetch, K; Rekol, H; Sokha, M; Sovannaroth, S; Soviet, U; Tarning, J; Tripura, R; von Seidlein, L; Waithira, N; White, NJ | 1 |
Dondorp, AM; Maude, RJ; Tarning, J; von Seidlein, L; White, NJ | 1 |
Alemayehu, GS; Dinka, H; Golassa, L; Hassen, J | 1 |
Aweeka, F; Ehrlich, H; Freeman, T; French, J; Goodwin, J; Huang, L; Kajubi, R; Kay, K; Li, F; Mwebaza, N; Ou, J; Parikh, S; Riggs, M; Ruiz-Garcia, A; Wade, M; Wang, K | 1 |
Bibe, AF; Earland, DE; Ferrão, J; Novela, A; Searle, KM | 1 |
Chenet, SM; Cortés, LJ; Guerra, AP; Lucchi, NW; Macedo de Oliveira, A; Olivera, MJ | 1 |
Abuaku, B; Afrane, Y; Amoah, LE; Cui, L; Duah-Quashie, NO; Duan, M; Huang, Y; Li, X; Pan, M; Qin, Y; Sun, K; Wang, X; Yang, Q; Yang, Z; Zeng, W; Zhao, H; Zhao, W; Zhou, L; Zhu, W | 1 |
Adegnika, AA; Akinosho, MA; Davi, SD; Dimessa-Mbadinga, LB; Handrich, C; Kreidenweiss, A; Kremsner, PG; Lell, B; Mombo-Ngoma, G; Ndzebe-Ndoumba, WF; Nordmann, T; Okwu, DG; Ramharter, M; Stelzl, D; Veletzky, L; Zoleko-Manego, R | 1 |
Andrianaranjaka, VHI; Dodoson, BT; Fenomanana, J; Rakotoarisoa, MA; Ratsimbasoa, A | 1 |
Augusto, O; Byamugisha, J; Clerk, C; Dellicour, S; Desai, M; Gomes, M; Guérin, PJ; Hill, J; Kagawa, M; Kariuki, S; Kisinza, W; Manyando, C; McGready, R; Mehta, U; Mosha, D; Mrema, S; Njunju, EM; Nosten, F; Rouamba, T; Rulisa, S; Saito, M; Sevene, E; Singlovic, J; Stepniewska, K; Stergachis, A; Ter Kuile, FO; Tinto, H; Vala, A; van Eijk, AM; Were, E; Yore, M | 1 |
Abera, A; Alemayehu, BH; Anand, A; Assefa, A; Bekele, W; Dilu, D; Etana, K; Ezema, B; Girma, S; Haile, M; Hwang, J; Minta, AA; Mohammed, H; Moriarty, LF; Murphy, M; Sime, H; Solomon, H; Svigel, SS; Tadesse, M; Tadesse, Y; Tasew, G; Teka, H; Woyessa, A; Zhou, Z | 1 |
Abongo, G; Basara, BB; Baseke, J; Bongo, GS; Day, NJP; Dhorda, M; Dondorp, AM; Fanello, C; Kayembe, DK; Maitland, K; Muhindo, R; Mukaka, M; Namayanja, C; Ndjowo, PO; Okalebo, CB; Olupot-Olupot, P; Onyamboko, MA; Onyas, P; Peerawaranun, P; Tarning, J; Taya, C; Taylor, WR; Titin, H; Uyoga, S; Waithira, N; Weere, W; Williams, TN | 1 |
Falade, CO; Funwei, RI; Hammed, WA; Ojurongbe, O; Uyaiabasi, GN; Walker, O | 1 |
Adedeji, WA; Dairo, MD; Fehintola, FA; Nguku, PM; Oyemakinde, A | 1 |
Abay, SM; Assefa, A; Assefa, G; Bekele, W; Gidey, B; Gubae, K; Haile, M; Hailgiorgis, H; Mare, AK; Mohammed, H; Sime, H; Tasew, G | 1 |
Adams, M; Buchwald, AG; Divala, TH; Earland, DE; Laufer, MK; Laurens, MB; Mallewa, JE; Miller, J; Mungwira, RG; Nampota-Nkomba, N; Nyangulu, W; Nyirenda, OM; Parikh, S; Plowe, CV; Taylor, TE; van Oosterhout, JJ | 1 |
Mace, KE; Schultz, JS; Tan, KR | 1 |
Abd-Rahman, AN; Barber, BE; Birrell, GW; Edstein, MD; Leelasena, I; Llewellyn, S; Marquart, L; McCarthy, JS; Moehrle, JJ; Potter, AJ; Sahai, N; Shanks, GD; Webster, R; Wesche, D | 1 |
Adjei, GO; Ahorhorlu, SY; Alifrangis, M; Duah-Quashie, NO; Dzudzor, B; Hansson, H; Jensen, RW; Kudzi, W; Nartey, ET; Quashie, NB; Wang, CW; Zoiku, F | 1 |
Adebayo, IA; Adeyemo, RO; Akinola, SA; Albert, O; Bwogo, P; John, O; Maniga, JN; Martin, O; Muchiri, JN; Onkoba, SK; Rael, M; Samuel, M; Sankarapandian, V; Wilberforce, M | 1 |
Batty, KT; Davis, TME; Kasian, B; Laman, M; Lorry, L; Manning, L; Moore, BR; Pomat, W; Robinson, LJ; Salman, S; Tesine, P; Woon, SA; Yadi, G; Yambo, P | 1 |
Ashton, RA; Bennett, A; Burnett, S; Eisele, TP; Hainsworth, M; Hamainza, B; Lungu, C; Miller, JM; Porter, T; Rutagwera, MI; Silumbe, K; Slater, H | 1 |
Abala, C; Nyeko, R; Obiya, EM; Otim, F | 1 |
Bogoch, II; Halani, S | 1 |
Ahmed, RA; Begum, A; Hussain, SSA; Kalita, D; Kumar, A; Kumar, G; Shankar, H; Singh, K; Suri, HS; Swargiary, A | 1 |
Akala, HM; Amwoma, JG; Andagalu, BM; Chemwor, GC; Cheruiyot, AC; Egbo, TE; Garges, EC; Juma, DW; Juma, JA; Kamau, E; Mwakio, EW; Ogutu, BR; Okoth, RO; Onyango, IA; Opot, BH; Roth, AL; Wakoli, DM; Watson, OJ; Yedah, RA | 1 |
Aygen, B; Kalın Ünüvar, G; Türe, Z; Yaman, O; Yıldız, O | 1 |
Djissem, PE; Manyeh, AK; Tetteh, JA | 1 |
Aina, O; Awolola, ST; Babatunde, S; David, AN; Ekama, SO; Happi, CT; Ijezie, SN; Mohammed, AB; Mokuolu, O; Musa, AZ; Ogbulafor, N; Oguche, S; Okafor, H; Olukosi, AY; Ozor, L; Salako, BL; Uhomoibhi, PE; Wammanda, R | 1 |
Adehossi, E; Arzika, II; Lamine, MM; Lobo, NF; Mahamadou, A; Mahmud, O; Maman Laminou, I; Sandrine, H; Sarr, D; Sarrasin-Hubert, V; Tidjani, IA | 1 |
Adedapo, AD; Anjorin, OE; Falade, CO; Funwei, RI; Michael, OS; Mokuolu, OA; Olusanya, AL; Olusola, FI; Orimadegun, AE; Orimadegun, BE | 1 |
Chepngetich, J; Gachie, B; Gathirwa, J; Kiboi, D; Kimani, F; Magoma, G; Muriithi, B; Mwitari, P; Onchieku, N; Thiong'o, K | 1 |
Agyemang, SA; Aikins, M; Amon, S; Aryeetey, GC; Baabu, BS; Dwomoh, D; Malm, K; Nonvignon, J; Novignon, J; Owusu, R; Peprah, NY | 1 |
Buzibye, A; Nakalembe, L; Nsobya, S; Ocan, M; Omali, D; Otike, C | 1 |
Adebanjo, IM; Ademowo, OG; Ajayi, AM | 1 |
Amambua-Ngwa, A; Dugassa, S; Golassa, L; Jawara, A; Oboh, M; Oriero, E; Tadele, G | 1 |
Adhikari, B; Callery, JJ; Cheah, PY; Conradis-Jansen, F; Dondorp, AM; Ean, M; Jongdeepaisal, M; Khonputsa, P; Maude, RJ; Müller, O; Murgia, R; Pell, C; Peto, TJ; Sovannaroth, S; Tripura, R; von Seidlein, L | 1 |
Bernieri, F; Cavallari, S; Doderer-Lang, C; Guidetti, C; L'Episcopia, M; Menard, D; Perrotti, E; Priuli, GB; Severini, C | 1 |
Abel, L; Ambani, G; Boyce, M; Kirui, J; Laktabai, J; Malinga, J; Menya, D; Nalianya, E; Namae, J; O'Meara, W; Sang, E | 1 |
Ayrık Demir, A; Erdoğan, E; Türe Yüce, Z; Yaman, O; Yıldız, O; Yürük, M | 1 |
Aide, P; Baraka, V; Bassat, Q; Cousin, M; David, A; Gesase, S; Gwasupika, J; Hachizovu, S; Makenga, G; Manyando, C; Nhama, A; Ntizimira, CR; Obunge, O; Otsyula, N; Pathan, R; Risterucci, C; Su, G; Tshefu, KA | 1 |
Aguas, R; Amaratunga, C; Boni, MF; Dhorda, M; Dondorp, AM; Gao, B; Nguyen, TD; Tran, TN; White, NJ | 1 |
Abdelkader, O; Boulotigam, K; Djimadoum, M; Djimrassengar, H; Doderer-Lang, C; Hassoumi, M; Issa, AH; Issa, MS; Mahamat, MHT; Menard, D; Ndihiokubwayo, JB; Rasmussen, C; Saleh, IDM; Warsame, M | 1 |
Bauserman, M; Laktabai, J; Rent, S; Taylor, SM; Tshefu, AK | 1 |
Dellicour, S; Gutman, JR; Hill, J; Ochodo, E; Osoro, CB; Ter Kuile, F; Young, T | 1 |
Dellicour, S; Gutman, JR; Hill, J; Ochodo, E; Osoro, CB; Ter Kuile, FO; Young, T | 1 |
Boni, MF; Kabera, M; Li, H; Ngabonziza, JCS; Nguyen, TD; Tran, KT; Tran, TN; Uwimana, A; Zupko, RJ | 1 |
Cai, J; Chen, G; Hu, G; Jin, L; Li, J; Li, Q; Li, S; Li, Y; Qian, J; Zhang, X; Zhou, Q | 1 |
Ahmed, K; Culleton, R; Dony, JJF; Fornace, KM; Habil, B; Hassan, MR; Hod, R; Ibrahim, SSA; Jantim, A; Jeffree, MS; Jiee, SF; Mohamed, AFB; Naserrudin, NA | 1 |
D'Alessandro, U; Dabira, ED; Diakite, H; Djimde, M; Dorlo, TP; Erhart, A; González, R; Kabore, B; Kayentao, K; Keita, M; Macuacua, S; Menendez, C; Mens, P; Muhindo, HM; Piqueras, M; Sagara, I; Schallig, H; Sevene, E; Tinto, H; Traore, M; Tshiongo, JK; Vala, A | 1 |
Abade, A; O'Meara, WP; Odhiambo, F; Odhiambo, FO; Owiny, M; Oyugi, EO | 1 |
Bamisaiye, A; Basara, BB; Baseke, J; Day, NPJ; Fanello, C; Kayembe, DK; Maitland, K; Muhindo, R; Mukaka, M; Namayanja, C; Ndjowo, PO; Okalebo, CB; Olupot-Olupot, P; Onyamboko, MA; Onyas, P; Taya, C; Taylor, WRJ; Titin, H; Uyoga, S; Were, W; Williams, TN | 1 |
Acharya, S; Arnold, L; Chico, RM; Gore-Langton, GR; Lufele, E; Moore, BR; Price, RN; Rogerson, SJ; Ter Kuile, FO; Thriemer, K; Unger, HW; van Eijk, AM; Wu, C | 1 |
Ahoua Alou, LP; Camara, S; Koffi, AA; N'Guessan, B; N'Guessan, R; Oumbouke, WA; Rowland, M; Thomas, MB; Tia, IZ; Wolie, RZ; Zoh, MG | 1 |
Abate, DT; Alam, MS; Anose, RT; Baird, JK; Christian, M; Degaga, TS; Ekawati, LL; Hailu, A; Hossain, MS; Karahalios, A; Kibria, MG; Kiros, FG; Lee, G; Ley, B; Mnjala, H; Panggalo, LV; Price, RN; Rajasekhar, M; Rumaseb, A; Sadhewa, A; Satyagraha, AW; Simpson, JA; Sutanto, I; Tego, TT; Thriemer, K; Weston, S; Woyessa, A | 1 |
9 review(s) available for artemether and cgp-56697
Article | Year |
---|---|
Artemisinin--an innovative cornerstone for anti-malaria therapy.
Topics: Animals; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisia annua; Artemisinins; Biomass; Crops, Agricultural; Drug Combinations; Drug Design; Drug Resistance; Drugs, Chinese Herbal; Ethanolamines; Fluorenes; Humans; Malaria; Models, Molecular; Molecular Structure; Technology, Pharmaceutical; Treatment Outcome | 2008 |
Efficacy of Single-Dose Primaquine With Artemisinin Combination Therapy on Plasmodium falciparum Gametocytes and Transmission: An Individual Patient Meta-Analysis.
Topics: Animals; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Humans; Malaria, Falciparum; Plasmodium falciparum; Primaquine | 2022 |
Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Chloroquine; Drug Combinations; Female; Humans; Malaria; Parasitemia; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Parasitic; Pyrimethamine; Quinine; Sulfadoxine | 2021 |
Comparative effect of dihydroartemisinin-piperaquine and artemether-lumefantrine on gametocyte clearance and haemoglobin recovery in children with uncomplicated Plasmodium falciparum malaria in Africa: a systematic review and meta-analysis of randomized c
Topics: Africa; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Combinations; Fluorenes; Hemoglobins; Humans; Malaria, Falciparum; Plasmodium falciparum; Quinolines; Randomized Controlled Trials as Topic | 2021 |
Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: A systematic review and meta-analysis.
Topics: Africa South of the Sahara; Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Drug Combinations; Ethanolamines; Humans; Malaria; Malaria, Falciparum; Piperazines; Plasmodium falciparum; Quinolines | 2022 |
Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, Preschool; Humans; Plasmodium falciparum; Recurrence | 2022 |
Drug-Drug Interactions of Artemisinin-Based Combination Therapies in Malaria Treatment: A Narrative Review of the Literature.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Humans; Malaria; Malaria, Falciparum | 2022 |
Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis.
Topics: Abortion, Spontaneous; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Drug Combinations; Ethanolamines; Female; Humans; Malaria; Malaria, Falciparum; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, First; Prospective Studies; Quinine; Stillbirth | 2023 |
The effect and control of malaria in pregnancy and lactating women in the Asia-Pacific region.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Asia; Female; Humans; Lactation; Malaria; Malaria, Falciparum; Pregnancy | 2023 |
40 trial(s) available for artemether and cgp-56697
Article | Year |
---|---|
A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschool; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Pyrimethamine; Sesquiterpenes; Sulfadoxine | 1998 |
Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years.
Topics: Acute Disease; Administration, Oral; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschool; Chloroquine; Drug Administration Schedule; Drug Combinations; Ethanolamines; Female; Fluorenes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Sesquiterpenes; Tanzania; Treatment Outcome | 1998 |
Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.
Topics: Adolescent; Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Double-Blind Method; Drug Combinations; Ethanolamines; Female; Fluorenes; Humans; Lumefantrine; Malaria; Male; Middle Aged; Sesquiterpenes; Treatment Outcome | 1998 |
Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Ethanolamines; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Random Allocation; Sesquiterpenes; Thailand; Time Factors | 1999 |
Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Chromatography, High Pressure Liquid; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Interactions; Electrocardiography; Ethanolamines; Fluorenes; Heart; Humans; Male; Mefloquine; Middle Aged; Sesquiterpenes | 2000 |
Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Follow-Up Studies; HIV Infections; Humans; Infant; Longitudinal Studies; Malaria, Falciparum; Male; Quinolines; Risk Factors; Treatment Outcome; Uganda | 2009 |
Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Follow-Up Studies; Gametogenesis; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Nigeria; Plasmodium falciparum; Polymerase Chain Reaction; Pyrimethamine; Sulfalene; Treatment Outcome | 2010 |
Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges.
Topics: Age Factors; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Body Weight; Child; Child, Preschool; Drug Combinations; Ethanolamines; Female; Fluorenes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Plasmodium falciparum; Polymerase Chain Reaction; Time Factors; Treatment Outcome | 2011 |
Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Benin.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Benin; Child, Preschool; Drug Combinations; Ethanolamines; Female; Fluorenes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male | 2016 |
Can Rapid Diagnostic Testing for Malaria Increase Adherence to Artemether-Lumefantrine?: A Randomized Controlled Trial in Uganda.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Ethanolamines; Female; Fluorenes; Humans; Lumefantrine; Malaria; Male; Medication Adherence; Point-of-Care Testing; Uganda | 2016 |
A Randomized Controlled Trial of Three- versus Five-Day Artemether-Lumefantrine Regimens for Treatment of Uncomplicated Plasmodium falciparum Malaria in Pregnancy in Africa.
Topics: Adult; Africa; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Female; Humans; Malaria, Falciparum; Pregnancy; Young Adult | 2020 |
Randomized Controlled Trial of the Electrocardiographic Effects of Four Antimalarials for Pregnant Women with Uncomplicated Malaria on the Thailand-Myanmar Border.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Drug Therapy, Combination; Electrocardiography; Female; Humans; Malaria; Malaria, Falciparum; Myanmar; Pregnancy; Pregnant Women; Quinolines; Thailand | 2021 |
Efficacy and safety of artesuante-amodiaquine and artemether lumefantrine, the first line malaria treatment in six sentinel's sites of Côte d'Ivoire, West Africa.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Cote d'Ivoire; Drug Combinations; Ethanolamines; Fluorenes; Humans; Infant; Malaria; Malaria, Falciparum; Treatment Outcome | 2020 |
A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Malaria; Malaria, Falciparum; Mefloquine; Myanmar; Pregnancy; Premature Birth; Quinolines; Thailand | 2021 |
Effectiveness and safety of reactive focal mass drug administration (rfMDA) using dihydroartemisinin-piperaquine to reduce malaria transmission in the very low-endemic setting of Eswatini: a pragmatic cluster randomised controlled trial.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Eswatini; Humans; Malaria; Mass Drug Administration; Quinolines | 2021 |
High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine.
Topics: Animals; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Drug Resistance; Gabon; Humans; Malaria, Falciparum; Mutation; Parasites; Plasmodium falciparum; Prevalence; Protozoan Proteins; Rwanda | 2022 |
Study protocol: an open-label individually randomised controlled trial to assess the efficacy of artemether-lumefantrine prophylaxis for malaria among forest goers in Cambodia.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Cambodia; Forests; Humans; Malaria; Malaria, Falciparum; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria.
Topics: Adult; Africa South of the Sahara; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Drug Combinations; Ethanolamines; Fluorenes; Humans; Indoles; Malaria, Falciparum; Plasmodium falciparum; Spiro Compounds; Treatment Outcome | 2022 |
Joint modelling of multivariate longitudinal clinical laboratory safety outcomes, concomitant medication and clinical adverse events: application to artemisinin-based treatment during pregnancy clinical trial.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Female; Humans; Laboratories; Malaria, Falciparum; Pregnancy | 2021 |
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults.
Topics: Adolescent; Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Drug Combinations; Ethanolamines; Female; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Male; Middle Aged; Nitriles; Pyrazoles; Pyrimidines; Single-Blind Method; Young Adult | 2022 |
Effectiveness and safety of artesunate-amodiaquine versus artemether-lumefantrine for home-based treatment of uncomplicated Plasmodium falciparum malaria among children 6-120 months in Yaoundé, Cameroon: a randomized trial.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Cameroon; Child; Drug Combinations; Ethanolamines; Humans; Infant; Malaria, Falciparum; Plasmodium falciparum; Treatment Outcome | 2022 |
Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Ethanolamines; Female; Fluorenes; Humans; Malaria; Malaria, Falciparum; Male; Plasmodium falciparum; Recurrence; Vomiting | 2022 |
Artemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Grande Comore island: an open-label, non-randomised controlled trial.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Ethanolamines; Fluorenes; Humans; Malaria; Malaria, Falciparum; Piperazines; Plasmodium falciparum; Quinolines | 2022 |
Safety, Tolerability, and Parasite Clearance Kinetics in Controlled Human Malaria Infection after Direct Venous Inoculation of Plasmodium falciparum Sporozoites: A Model for Evaluating New Blood-Stage Antimalarial Drugs.
Topics: Adult; Animals; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Humans; Malaria; Parasitemia; Parasites; Plasmodium falciparum; Sporozoites | 2022 |
The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, Preschool; Drug Combinations; Ethanolamines; Fluorenes; Humans; Infant; Lumefantrine; Malaria; Malaria, Falciparum; Parasitemia; Prospective Studies; Reinfection; Uganda | 2023 |
Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Cambodia; Chemoprevention; Drug Combinations; Ethanolamines; Fluorenes; Humans; Lumefantrine; Malaria; Malaria, Falciparum | 2023 |
Modelling the optimal dosing schedule for artemether-lumefantrine chemoprophylaxis against malaria.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Chemoprevention; Drug Combinations; Ethanolamines; Fluorenes; Humans; Malaria; Malaria, Falciparum | 2022 |
Effectiveness of antimalarial drug combinations in treating concomitant urogenital schistosomiasis in malaria patients in Lambaréné, Gabon: A non-randomised event-monitoring study.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Drug Combinations; Ethanolamines; Gabon; Humans; Malaria; Malaria, Falciparum; Schistosomiasis haematobia | 2022 |
Comparative effect of artemether-lumefantrine and artesunate-amodiaquine on gametocyte clearance in children with uncomplicated Plasmodium falciparum malaria in Madagascar.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Child; Child, Preschool; Drug Combinations; Ethanolamines; Humans; Infant; Madagascar; Malaria, Falciparum; Plasmodium falciparum | 2022 |
Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Chloroquine; Ethiopia; Humans; Malaria, Falciparum; Malaria, Vivax; Plasmodium falciparum; Plasmodium vivax | 2022 |
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, n
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Democratic Republic of the Congo; Female; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; Humans; Infant; Malaria, Falciparum; Male; Plasmodium falciparum; Primaquine; Uganda; World Health Organization | 2023 |
Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Ethanolamines; Fluorenes; HIV Infections; Humans; Lumefantrine; Malaria; Malaria, Falciparum; Malawi; Treatment Outcome | 2023 |
Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Humans; Malaria; Malaria, Falciparum; Malaria, Vivax; Parasitemia; Plasmodium vivax; Primaquine; Time-to-Treatment | 2023 |
Therapeutic response to artemisinin combination therapies among individuals with Plasmodium falciparum single infection vs mixed Plasmodium species infections: a retrospective posthoc analysis in Kisumu County, western Kenya.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Humans; Kenya; Malaria; Malaria, Falciparum; Plasmodium falciparum; Quinolines; Reinfection; Retrospective Studies | 2023 |
Efficacy and safety of pyronaridine-artesunate versus artemether-lumefantrine in the treatment of acute uncomplicated malaria in children in South-West Nigeria: an open-labelled randomized controlled trial.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Combinations; Ethanolamines; Female; Fluorenes; Humans; Infant; Malaria, Falciparum; Male; Nigeria; Retrospective Studies; Treatment Outcome | 2023 |
Community engagement among forest goers in a malaria prophylaxis trial: implementation challenges and implications.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Female; Forests; Humans; Malaria | 2023 |
Supply-side and demand-side factors influencing uptake of malaria testing services in the community: lessons for scale-up from a post-hoc analysis of a cluster randomised, community-based trial in western Kenya.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Community Health Services; Community Health Workers; Fever; Humans; Kenya; Malaria; Research Design | 2023 |
Efficacy and safety of pyronaridine-artesunate (PYRAMAX) for the treatment of
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Humans; Infant; Malaria; Malaria, Falciparum; Pregnancy; Pregnant Women; Randomized Controlled Trials as Topic; Sub-Saharan African People; Treatment Outcome | 2023 |
Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low-dose primaquine or placebo.
Topics: alpha-Thalassemia; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Child, Preschool; Female; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; Humans; Malaria, Falciparum; Male; Plasmodium falciparum; Primaquine | 2023 |
Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Australia; Humans; Malaria; Malaria, Falciparum; Malaria, Vivax; Parasitemia; Plasmodium falciparum; Plasmodium vivax; Primaquine | 2023 |
93 other study(ies) available for artemether and cgp-56697
Article | Year |
---|---|
Changes in antioxidant status and biochemical indices after acute administration of artemether, artemether-lumefantrine and halofantrine in rats.
Topics: Administration, Oral; Alanine Transaminase; Animals; Antimalarials; Antioxidants; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Aspartate Aminotransferases; Bilirubin; Biomarkers; Blood Urea Nitrogen; Catalase; Creatinine; Drug Combinations; Ethanolamines; Fluorenes; Glutathione; Glutathione Transferase; Intubation, Gastrointestinal; Kidney; Lipid Peroxidation; Liver; Male; Phenanthrenes; Rats; Rats, Wistar; Superoxide Dismutase; Time Factors | 2008 |
Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine.
Topics: Administration, Oral; Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Chromatography, Liquid; Drug Combinations; Ethanolamines; Fluorenes; Human Experimentation; Humans; Male; Middle Aged; Pakistan; Plasma; Tandem Mass Spectrometry; Time Factors | 2010 |
The effect of lopinavir/ritonavir on the antimalarial activity of artemether or artemether/lumefantrine in a mouse model of Plasmodium berghei.
Topics: Animals; Anti-Retroviral Agents; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Coinfection; Disease Models, Animal; Drug Combinations; Drug Interactions; Ethanolamines; Fluorenes; HIV Infections; Lopinavir; Malaria; Mice; Plasmodium berghei; Ritonavir | 2015 |
Baseline in vivo, ex vivo and molecular responses of Plasmodium falciparum to artemether and lumefantrine in three endemic zones for malaria in Colombia.
Topics: Adolescent; Adult; Aged; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Colombia; DNA Copy Number Variations; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Lumefantrine; Malaria; Male; Middle Aged; Parasitemia; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Young Adult | 2017 |
Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method.
Topics: Adolescent; Amodiaquine; Antimalarials; Arrhythmias, Cardiac; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, Preschool; Drug Combinations; Ethanolamines; Female; Fluorenes; Heart Rate; Humans; Long QT Syndrome; Malaria; Malaria, Falciparum; Male; Quinolines; Young Adult | 2019 |
Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Drug Interactions; Heterocyclic Compounds, 3-Ring; Oxazines; Piperazines; Pyridones | 2019 |
Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine".
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Drug Interactions; Heterocyclic Compounds, 3-Ring; Oxazines; Piperazines; Pyridones | 2019 |
[The treatment of malaria].
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Chloroquine; Drug Combinations; Drug Therapy, Combination; Female; Humans; Malaria; Malaria Vaccines; Male; Netherlands; Pregnancy; Travel | 2019 |
Adherence to antimalarial drug policy among doctors in Delta State, Nigeria: implications for malaria control.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Chloroquine; Drug Resistance, Microbial; Female; Guideline Adherence; Health Policy; Humans; Malaria, Falciparum; Male; Middle Aged; Nigeria; Plasmodium falciparum; Practice Guidelines as Topic; Practice Patterns, Physicians'; Quinine; Surveys and Questionnaires; Young Adult | 2019 |
Safety and tolerability of artesunate-amodiaquine, artemether-lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo.
Topics: Amodiaquine; Anti-Bacterial Agents; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Child, Preschool; Clindamycin; Democratic Republic of the Congo; Drug Combinations; Female; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Plasmodium falciparum; Quinine | 2019 |
Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by
Topics: Artemether; Artemether, Lumefantrine Drug Combination; Cytochrome P-450 CYP2B6; Genotype; HIV; Nevirapine; Polymorphism, Genetic | 2020 |
Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Interactions; Female; HIV Infections; Humans; Lumefantrine; Malaria; Malaria, Falciparum; Pregnancy; Prospective Studies; Uganda; Young Adult | 2020 |
Plasmodium falciparum Isolates Carrying
Topics: Alleles; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Cross-Sectional Studies; Drug Resistance; Humans; Indonesia; Malaria, Falciparum; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Protozoan Proteins | 2020 |
Case report: recurrence of Plasmodium vivax malaria due to defective cytochrome P450 2D6 function in Pos Lenjang, Pahang, Malaysia.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Cytochrome P-450 CYP2D6; Humans; Malaria, Vivax; Malaysia; Plasmodium vivax; Primaquine; Recurrence | 2020 |
Teratogen update: Malaria in pregnancy and the use of antimalarial drugs in the first trimester.
Topics: Animals; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Female; Malaria; Placenta; Pregnancy; Rabbits; Rats; Teratogens | 2020 |
Self-medication practice with antimalarials & the determinants of malaria treatment-seeking behavior among postpartum mothers in a rural community in Nigeria.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Cross-Sectional Studies; Female; Humans; Infant, Newborn; Malaria; Mothers; Nigeria; Postpartum Period; Rural Population | 2021 |
Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine.
Topics: Africa; Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Drug Combinations; Ethanolamines; Fluorenes; Heterocyclic Compounds, 3-Ring; Humans; Malaria, Falciparum; Oxazines; Piperazines; Pyridones | 2021 |
Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkina Faso; Child; Child, Preschool; Cross-Sectional Studies; Drug Combinations; Feasibility Studies; Female; Humans; Malaria; Malaria, Falciparum; Pregnancy | 2021 |
Electrocardiographic effect of artemisinin-piperaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine treatment in falciparum malaria patients.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Electrocardiography; Humans; Malaria; Malaria, Falciparum; Quinolines | 2021 |
Reply to Rasmussen and Ringwald, "Continued Low Efficacy of Artemether-Lumefantrine in Angola?"
Topics: Angola; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Humans; Malaria, Falciparum | 2021 |
Continued Low Efficacy of Artemether-Lumefantrine in Angola?
Topics: Angola; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Lumefantrine | 2021 |
Antimalarial drug resistance markers in human immunodeficiency virus (HIV)-positive and HIV-negative adults with asymptomatic malaria infections in Port Harcourt, Nigeria.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Drug Combinations; Drug Resistance; HIV; Humans; Malaria; Malaria, Falciparum; Nigeria; Plasmodium falciparum; Protozoan Proteins | 2021 |
Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Burkina Faso; Drug Combinations; Ethanolamines; Humans; Malaria, Falciparum; Mali; Parasitemia; Plasmodium falciparum; Treatment Failure | 2021 |
Novel Dipeptides Bearing Sulfonamide as Antimalarial and Antitrypanosomal Agents: Synthesis and Molecular Docking.
Topics: Animals; Antimalarials; Antiprotozoal Agents; Artemether; Artemether, Lumefantrine Drug Combination; Dipeptides; Mice; Molecular Docking Simulation; Parasitic Sensitivity Tests; Structure-Activity Relationship; Sulfonamides | 2022 |
Artemether-lumefantrine treatment failure of uncomplicated Plasmodium falciparum malaria in travellers coming from Angola and Mozambique.
Topics: Angola; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Humans; Malaria, Falciparum; Male; Middle Aged; Mozambique; Plasmodium falciparum; Treatment Failure | 2021 |
The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Ethanolamines; Female; Fluorenes; Humans; Lumefantrine; Malaria; Malaria, Falciparum; Male; Middle Aged; Plasmodium knowlesi | 2022 |
An assessment of the knowledge, practices and resources during the delivery of malaria health care services among private health care practitioners: a cross section study in the Mid-Western Region of Uganda.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Cross-Sectional Studies; Delivery of Health Care; Health Facilities; Humans; Malaria; Private Sector; Uganda | 2021 |
Artemisinin derivative-containing therapies and abnormal hemoglobin: Do we need to adapt the treatment?
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Cote d'Ivoire; Drug Combinations; Ethanolamines; Hemoglobins, Abnormal; Humans; Malaria, Falciparum; Plasmodium falciparum; Retrospective Studies; Treatment Outcome | 2021 |
Fatal case of delayed-onset haemolytic anaemia after oral artemether-lumefantrine.
Topics: Anemia, Hemolytic; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Drug Combinations; Female; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Middle Aged | 2021 |
Trends and predictive factors for treatment failure following artemisinin-based combination therapy among children with uncomplicated malaria in Ghana: 2005-2018.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Combinations; Ghana; Humans; Infant; Malaria; Malaria, Falciparum; Treatment Failure | 2021 |
Report of a Homeopathic Medication Regimen Containing Artemether/Lumefantrine in a Patient With Rheumatoid Arthritis.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Arthritis, Rheumatoid; Humans; Lumefantrine | 2021 |
Implementation of community case management of malaria in malaria endemic counties of western Kenya: are community health volunteers up to the task in diagnosing malaria?
Topics: Adult; Aged; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Case Management; Community Health Workers; Diagnostic Tests, Routine; Female; Humans; Kenya; Malaria; Middle Aged; Public Health; Volunteers | 2022 |
Molecular surveillance for operationally relevant genetic polymorphisms in Plasmodium falciparum in Southern Chad, 2016-2017.
Topics: Adolescent; Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Chad; Child; Child, Preschool; Drug Resistance; Female; Humans; Male; Middle Aged; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Young Adult | 2022 |
A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Child, Preschool; Cytochrome P-450 CYP2D6; Female; Humans; Infant; Plasmodium falciparum; Primaquine; Tanzania | 2022 |
School-Based Malaria Screening and Treatment Reduces Plasmodium falciparum Infection and Anemia Prevalence in Two Transmission Settings in Malawi.
Topics: Anemia; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Humans; Malaria; Malaria, Falciparum; Malawi; Plasmodium falciparum; Prevalence; Prospective Studies; Schools | 2022 |
Plasmodium malariae after successful treatment of P. falciparum malaria with artemether-lumefantrine.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Fluorenes; Humans; Malaria; Malaria, Falciparum; Plasmodium falciparum; Plasmodium malariae | 2022 |
Health care provider practices in diagnosis and treatment of malaria in rural communities in Kisumu County, Kenya.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Diagnostic Tests, Routine; Fever; Health Personnel; Humans; Kenya; Malaria; Malaria, Falciparum; Real-Time Polymerase Chain Reaction; Rural Population; Sensitivity and Specificity | 2022 |
Artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Child; Chloroquine; DNA Copy Number Variations; Female; Humans; Liberia; Malaria; Malaria, Falciparum; Membrane Transport Proteins; Plasmodium falciparum; Pregnancy | 2022 |
Prevalence of malaria among febrile patients and assessment of efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated malaria in Dolisie, Republic of the Congo.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Child; Congo; Drug Combinations; Fever; Humans; Malaria; Parasitemia; Prevalence | 2022 |
Prevalence of arps10, fd, pfmdr-2, pfcrt and pfkelch13 gene mutations in Plasmodium falciparum parasite population in Uganda.
Topics: Animals; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Resistance; Malaria; Malaria, Falciparum; Mutation; Parasites; Plasmodium falciparum; Prevalence; Protozoan Proteins; Uganda | 2022 |
[Monitoring the Efficacy of Artemether-Lumefantrine in the Treatment of Uncomplicated
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Central African Republic; Child; Cross-Sectional Studies; Drug Combinations; Ethanolamines; Fluorenes; Humans; Malaria; Malaria, Falciparum; Mutation; Treatment Outcome | 2021 |
The effect of sickle cell genotype on the pharmacokinetic properties of artemether-lumefantrine in Tanzanian children.
Topics: Anemia, Sickle Cell; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Ethanolamines; Fluorenes; Genotype; Humans; Lumefantrine; Malaria; Malaria, Falciparum; Tanzania | 2022 |
Attitudes, practices, and determinants of community care-seeking behaviours for fever/malaria episodes in the context of the implementation of multiple first-line therapies for uncomplicated malaria in the health district of Kaya, Burkina Faso.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Burkina Faso; Child; Cross-Sectional Studies; Female; Fever; Humans; Malaria; Patient Acceptance of Health Care; Pregnancy | 2022 |
Cost-Utility Analysis of Community Case Management for Malaria Control in Burundi.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Burundi; Case Management; Child; Child, Preschool; Cost-Benefit Analysis; Humans; Malaria | 2022 |
Multiple Plasmodium falciparum drug resistance polymorphisms identified in a pregnant woman with severe malaria and a concomitant spontaneous abortion in Cross River, Nigeria, West Africa.
Topics: Abortion, Spontaneous; Adult; Africa, Western; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Drug Resistance; Drug Resistance, Multiple; Female; Humans; Malaria; Malaria, Falciparum; Nigeria; Plasmodium falciparum; Pregnancy; Pregnant Women; Quinine | 2022 |
Quinine plus clindamycin vs artemether-lumefantrine for treatment of uncomplicated falciparum malaria in western Kenya.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Clindamycin; Drug Combinations; Ethanolamines; Fluorenes; Humans; Kenya; Malaria, Falciparum; Quinine | 2022 |
Transmission Blocking Activity of Low-dose Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum.
Topics: Adult; Animals; Anopheles; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Healthy Volunteers; Humans; Malaria; Malaria, Falciparum; Plasmodium falciparum; Sporozoites | 2023 |
Stakeholder perceptions on the deployment of multiple first-line therapies for uncomplicated malaria: a qualitative study in the health district of Kaya, Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Burkina Faso; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Malaria, Falciparum; Naphthyridines | 2022 |
Malaria Transmission Dynamics in a High-Transmission Setting of Western Kenya and the Inadequate Treatment Response to Artemether-Lumefantrine in an Asymptomatic Population.
Topics: Animals; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Humans; Kenya; Malaria; Malaria, Falciparum; Parasitemia; Plasmodium falciparum | 2023 |
Plasmodium falciparum merozoite invasion ligands, linked antimalarial resistance loci and ex vivo responses to antimalarials in The Gambia.
Topics: Animals; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Drug Resistance; Gambia; Ligands; Lumefantrine; Malaria; Malaria, Falciparum; Merozoites; Plasmodium falciparum; Protozoan Proteins | 2022 |
Pre-existing partner-drug resistance to artemisinin combination therapies facilitates the emergence and spread of artemisinin resistance: a consensus modelling study.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Consensus; Drug Resistance; Humans; Malaria, Falciparum; Plasmodium falciparum | 2022 |
Persistence of Residual Submicroscopic P. falciparum Parasitemia following Treatment of Artemether-Lumefantrine in Ethio-Sudan Border, Western Ethiopia.
Topics: Adolescent; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Disease Progression; Ethanolamines; Ethiopia; Fluorenes; Humans; Malaria; Malaria, Falciparum; Parasitemia; Plasmodium falciparum; Sudan; Treatment Outcome | 2022 |
Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria among Children in Western Kenya, 2016 to 2017.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Combinations; Ethanolamines; Fluorenes; Folic Acid Antagonists; Humans; Infant; Kenya; Malaria; Malaria, Falciparum; Piperazines; Plasmodium falciparum; Quinolines; Reinfection | 2022 |
Preparation and application of a specific single-chain variable fragment against artemether.
Topics: Antibodies, Monoclonal; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; DNA, Recombinant; Enzyme-Linked Immunosorbent Assay; Single-Chain Antibodies | 2022 |
Lumefantrine plasma concentrations in uncontrolled conditions among patients treated with artemether-lumefantrine for uncomplicated plasmodium falciparum malaria in Mwanza, Tanzania.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Combinations; Ethanolamines; Female; Fluorenes; Humans; Lumefantrine; Malaria; Malaria, Falciparum; Male; Plasmodium falciparum; Tanzania; Treatment Outcome | 2022 |
High prevalence of Pfcrt 76T and Pfmdr1 N86 genotypes in malaria infected patients attending health facilities in East Shewa zone, Oromia Regional State, Ethiopia.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Chloroquine; Drug Resistance; Ethiopia; Genotype; Health Facilities; Humans; Malaria; Malaria, Falciparum; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Prevalence; Protozoan Proteins | 2022 |
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Combinations; Fluorenes; HIV Infections; Humans; Lopinavir; Lumefantrine; Malaria; Malaria, Falciparum; Nevirapine; Ritonavir; Uganda | 2023 |
Plasmodium falciparum community prevalence and health-seeking behaviours in rural Sussundenga District, Mozambique.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Cross-Sectional Studies; Humans; Malaria; Malaria, Falciparum; Mozambique; Patient Acceptance of Health Care; Plasmodium falciparum; Prevalence | 2022 |
Molecular surveillance for anti-malarial drug resistance and genetic diversity of Plasmodium falciparum after chloroquine and sulfadoxine-pyrimethamine withdrawal in Quibdo, Colombia, 2018.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Chloroquine; Codon; Colombia; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum; Plasmodium falciparum; Polymorphism, Genetic; Pyrimethamine; Sulfadoxine | 2022 |
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Chloroquine; Ghana; Humans; Lumefantrine; Malaria, Falciparum; Plasmodium falciparum; Protozoan Proteins; Pyrimethamine | 2022 |
High prevalence of persistent residual parasitemia on days 3 and 14 after artemether-lumefantrine or pyronaridine-artesunate treatment of uncomplicated Plasmodium falciparum malaria in Nigeria.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Humans; Malaria, Falciparum; Merozoite Surface Protein 1; Nigeria; Parasitemia; Plasmodium falciparum; Prevalence | 2023 |
Pattern and predictors of medication use among adults in southwestern Nigeria: A community-based cross-sectional study.
Topics: Adult; Analgesics; Anti-Bacterial Agents; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Cross-Sectional Studies; Humans; Male; Middle Aged; Nigeria; Young Adult | 2023 |
Safety and therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at Shecha health centre, Arba Minch, Ethiopia.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Ethanolamines; Ethiopia; Fever; Fluorenes; Humans; Infant; Malaria, Falciparum; Plasmodium falciparum; Treatment Outcome | 2023 |
Return to Travel in the Coronavirus Disease 2019 Pandemic Recovery Period and Implications for Imported Malaria: Reinforcing Prevention, Early Diagnosis, and Appropriate Treatment of Malaria.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; COVID-19; COVID-19 Testing; Early Diagnosis; Humans; Malaria; Malaria, Falciparum; Pandemics; Travel; United States | 2023 |
Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Australia; Healthy Volunteers; Humans; Malaria, Falciparum; Parasitemia; Plasmodium falciparum | 2023 |
Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Combinations; Drug Tolerance; Ghana; Humans; Lumefantrine; Malaria; Malaria, Falciparum; Plasmodium falciparum | 2023 |
Novel Plasmodium falciparum k13 gene polymorphisms from Kisii County, Kenya during an era of artemisinin-based combination therapy deployment.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Resistance; Humans; Kenya; Malaria, Falciparum; Plasmodium falciparum; Polymorphism, Single Nucleotide; Protozoan Proteins | 2023 |
Effectiveness of community case management of malaria on severe malaria and inpatient malaria deaths in Zambia: a dose-response study using routine health information system data.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Case Management; Child; Community Health Workers; Health Information Systems; Humans; Inpatients; Malaria; Retrospective Studies; Zambia | 2023 |
Anti-malarial drug use, appropriateness and associated factors among children under-five with febrile illnesses presenting to a tertiary health facility: a cross sectional study.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, Preschool; Cross-Sectional Studies; Fever; Humans; Malaria | 2023 |
Weight-related malaria treatment failure with artemether-lumefantrine.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Drug Combinations; Ethanolamines; Fluorenes; Humans; Malaria; Malaria, Falciparum; Treatment Failure | 2023 |
Impact assessment of Intensified Malaria Control Project in transitioning a high malaria-endemic district to a low-endemic district: an epidemiological aspect.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Humans; Malaria; Malaria, Falciparum; Malaria, Vivax; Plasmodium falciparum; Plasmodium vivax | 2023 |
[Domestic Malaria Cases in Kayseri Province].
Topics: Adolescent; Animals; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Humans; Malaria; Malaria, Falciparum; Malaria, Vivax; Male; Parasitemia; Travel | 2023 |
Prevalence, trends and associated factors of malaria in the Shai-Osudoku District Hospital, Ghana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Child, Preschool; Cross-Sectional Studies; Ghana; Hospitals, District; Humans; Infant; Malaria; Malaria, Falciparum; Middle Aged; Prevalence; Young Adult | 2023 |
Design, Implementation, and Coordination of Malaria Therapeutic Efficacy Studies in Nigeria in 2018.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Drug Combinations; Ethanolamines; Fluorenes; Humans; Malaria; Malaria, Falciparum; Nigeria | 2023 |
Plasmodium falciparum kelch13 polymorphisms identified after treatment failure with artemisinin-based combination therapy in Niger.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Humans; Malaria, Falciparum; Niger; Plasmodium falciparum; Polymorphism, Single Nucleotide; Treatment Failure | 2023 |
Prevalence of mutations in the cysteine desulfurase IscS (Pfnfs1) gene in recurrent Plasmodium falciparum infections following artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) treatment in Matayos, Western Kenya.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Drug Combinations; Humans; Kenya; Lumefantrine; Malaria; Malaria, Falciparum; Mutation; Plasmodium falciparum; Prevalence; Quinolines; Reinfection | 2023 |
Cost of inappropriate prescriptions for uncomplicated malaria in Ghana.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Ghana; Humans; Inappropriate Prescribing; Malaria; Retrospective Studies | 2023 |
Pharmacopeial quality of artemether-lumefantrine anti-malarial agents in Uganda.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Cross-Sectional Studies; Humans; Lumefantrine; Malaria; Malaria, Falciparum; Uganda | 2023 |
Vitamin C-rich juice co-administration with artemether-lumefantrine ameliorates oxido-inflammatory responses in Plasmodium berghei-infected mice.
Topics: Animals; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Ascorbic Acid; Interleukin-6; Malaria; Malondialdehyde; Mice; Parasitemia; Plasmodium berghei; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2023 |
Clinical isolates of uncomplicated falciparum malaria from high and low malaria transmission areas show distinct pfcrt and pfmdr1 polymorphisms in western Ethiopia.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Chloroquine; Drug Resistance; Ethiopia; Humans; Lumefantrine; Malaria; Malaria, Falciparum; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Single Nucleotide; Protozoan Proteins | 2023 |
Polymorphism analysis of drug resistance markers in Plasmodium falciparum isolates from Benin.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Benin; Drug Combinations; Drug Resistance; Humans; Malaria; Malaria, Falciparum; Plasmodium falciparum; Protozoan Proteins; Pyrimethamine; Sulfadoxine; Tetrahydrofolate Dehydrogenase | 2023 |
[A Marginal Case of Malaria: An Interesting Malaria Story of Cameroon Origin].
Topics: Animals; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Cameroon; Coinfection; Humans; Malaria; Malaria, Vivax; Male; Middle Aged; Plasmodium; Plasmodium falciparum; Plasmodium vivax; Real-Time Polymerase Chain Reaction | 2023 |
Prescription patterns and compliance with World Health Organization recommendations for the management of uncomplicated and severe malaria: A prospective, real-world study in sub-Saharan Africa.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Drug Combinations; Humans; Infant, Newborn; Malaria; Malaria, Falciparum; Prescriptions; Prospective Studies; Tanzania; World Health Organization | 2023 |
Preventing antimalarial drug resistance with triple artemisinin-based combination therapies.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Folic Acid Antagonists | 2023 |
Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Chad: clinical and genetic surveillance.
Topics: Adult; Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Chad; Female; Humans; Malaria, Falciparum; Pregnancy; Prospective Studies | 2023 |
Malaria in Pregnancy: Key Points for the Neonatologist.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Female; Humans; Infant; Infant, Newborn; Malaria; Neonatologists; Pregnancy; Premature Birth | 2023 |
Healthcare provider and drug dispenser knowledge and adherence to guidelines for the case management of malaria in pregnancy in the context of multiple first-line artemisinin-based combination therapy in western Kenya.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Case Management; Cross-Sectional Studies; Female; Humans; Kenya; Malaria; Pregnancy; Quinine | 2023 |
Perceptions and drivers of healthcare provider and drug dispenser practices for the treatment of malaria in pregnancy in the context of multiple first-line therapies in western Kenya: a qualitative study.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Female; Health Personnel; Humans; Kenya; Malaria; Pharmaceutical Preparations; Pregnancy; Quinine | 2023 |
Modeling policy interventions for slowing the spread of artemisinin-resistant pfkelch R561H mutations in Rwanda.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Resistance; Humans; Malaria, Falciparum; Mutation; Plasmodium falciparum; Rwanda | 2023 |
Determine the enzymatic kinetic characteristics of CYP3A4 variants utilizing artemether-lumefantrine.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Cytochrome P-450 CYP3A; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Molecular Docking Simulation | 2023 |
The public health response to a Plasmodium malariae outbreak in Penampang district, Sabah during a COVID-19 movement control order.
Topics: Animals; Anopheles; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; COVID-19; Disease Outbreaks; Female; Humans; Malaria; Malaysia; Male; Mosquito Vectors; Pandemics; Plasmodium knowlesi; Plasmodium malariae; Public Health | 2023 |
Adherence to national malaria treatment guidelines in private drug outlets: a cross-sectional survey in the malaria-endemic Kisumu County, Kenya.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Cross-Sectional Studies; Fever; Humans; Kenya; Malaria; Surveys and Questionnaires | 2023 |
Attractive targeted sugar bait: the pyrrole insecticide chlorfenapyr and the anti-malarial pharmaceutical artemether-lumefantrine arrest Plasmodium falciparum development inside wild pyrethroid-resistant Anopheles gambiae s.s. mosquitoes.
Topics: Animals; Anopheles; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Carbohydrates; Female; Humans; Insecticide Resistance; Insecticides; Malaria; Malaria, Falciparum; Male; Mosquito Control; Mosquito Vectors; Plasmodium falciparum; Pyrethrins; Sugars | 2023 |